posted on 2025-05-11, 20:46authored bySean A. Hardy, Laura Liesinger, Lucy MurthaLucy Murtha, Malcolm R. Starkey, Daniel Scherr, Philip Hansbro, Gerald Hoefler, Gustavo Campos Ramos, Clement Cochain, Richard P. Harvey, Ruth Birner-Gruenberger, Andrew BoyleAndrew Boyle, Ralph Patrick, Peter P. Rainer, Maria Poettler, Lavinia Rech, Juergen Gindlhuber, Nishani S. Mabotuwana, DiyaaEldin Ashour, Verena Stangl, Mark BiglandMark Bigland
Irreversible fibrosis is a hallmark of myocardial infarction (MI) and heart failure. Extracellular matrix protein-1 (ECM-1) is up-regulated in these hearts, localized to fibrotic, inflammatory, and perivascular areas. ECM-1 originates predominantly from fibroblasts, macrophages, and pericytes/vascular cells in uninjured human and mouse hearts, and from M1 and M2 macrophages and myofibroblasts after MI. ECM-1 stimulates fibroblast-to-myofibroblast transition, up-regulates key fibrotic and inflammatory pathways, and inhibits cardiac fibroblast migration. ECM-1 binds HuCFb cell surface receptor LRP1, and LRP1 inhibition blocks ECM-1 from stimulating fibroblast-to-myofibroblast transition, confirming a novel ECM-1-LRP1 fibrotic signaling axis. ECM-1 may represent a novel mechanism facilitating inflammation-fibrosis crosstalk.